Baker McKenzie has advised the syndicate of 10 underwriters on the multi-tranche US$2.3 billion (equivalent) (upsized from USD 2 billion) SEC registered bond offering by certain subsidiaries of Teva Pharmaceutical Industries Limited.
BNP PARIBAS, BofA Securities, HSBC, IMI-Intesa Sanpaolo and J.P. Morgan acted as active joint book-running managers and Citigroup, Goldman Sachs Bank Europe SE, Mizuho, MUFG and PNC Capital Markets LLC acted as passive joint book-running managers.
Concurrently with the bond offering, Teva is running six-tiered, priority acceptance, fixed-price and fixed-spread tender offers to purchase up to USD 2.3 billion (upsized from US$2.0 billion) of certain of its other outstanding bonds. Affiliates of the active joint book-running managers are acting as dealer managers in the tender offers.
The cross-border, interdisciplinary Baker McKenzie team was led by London-based Capital Markets and Leveraged Finance partners David Becker, Rob Mathews and Ben Bierwirth, supported by associates Fani Chlampoutaki, Avni Devgan and Henry Gee and trainee Sunethra Reddy.
Other team members included partners Creighton Macy (Washington), Jeffrey Martino (New York), Barry Thompson (Los Angeles), Ross Staine (Houston) and Philippe Steffens (Amsterdam), of counsel Sven Bates (London), and associates Johanna Asplund (London), Thomas Tysowsky (Los Angeles), Jot Van Suijlen (Amsterdam) and Darley Maw (New York).
The Baker McKenzie team has a long history acting for underwriters, initial purchasers, lenders and other financial advisors to Teva, across Teva's capital structure.
The bond offering successfully closed on May 28, 2025 and the early settlement date of the tender offer is expected to be June 5, 2025.
BNP PARIBAS, BofA Securities, HSBC, IMI-Intesa Sanpaolo and J.P. Morgan acted as active joint book-running managers and Citigroup, Goldman Sachs Bank Europe SE, Mizuho, MUFG and PNC Capital Markets LLC acted as passive joint book-running managers.
Concurrently with the bond offering, Teva is running six-tiered, priority acceptance, fixed-price and fixed-spread tender offers to purchase up to USD 2.3 billion (upsized from US$2.0 billion) of certain of its other outstanding bonds. Affiliates of the active joint book-running managers are acting as dealer managers in the tender offers.
The cross-border, interdisciplinary Baker McKenzie team was led by London-based Capital Markets and Leveraged Finance partners David Becker, Rob Mathews and Ben Bierwirth, supported by associates Fani Chlampoutaki, Avni Devgan and Henry Gee and trainee Sunethra Reddy.
Other team members included partners Creighton Macy (Washington), Jeffrey Martino (New York), Barry Thompson (Los Angeles), Ross Staine (Houston) and Philippe Steffens (Amsterdam), of counsel Sven Bates (London), and associates Johanna Asplund (London), Thomas Tysowsky (Los Angeles), Jot Van Suijlen (Amsterdam) and Darley Maw (New York).
The Baker McKenzie team has a long history acting for underwriters, initial purchasers, lenders and other financial advisors to Teva, across Teva's capital structure.
The bond offering successfully closed on May 28, 2025 and the early settlement date of the tender offer is expected to be June 5, 2025.
Explore Our Newsroom